Dravet Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2024 | Companies- Takeda, Eisai, Stoke Therapeutics

DelveInsight's 'Dravet Syndrome Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dravet Syndrome therapies in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dravet Syndrome pipeline domain.
Key Takeaways from the Dravet Syndrome Pipeline Report
Over 15+ Dravet Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Dravet Syndrome market would significantly increase market revenue.
Leading Dravet Syndrome companies developing novel drug candidates to improve the Dravet Syndrome treatment landscape include Takeda, Eisai, Stoke Therapeutics, and others.
Promising Dravet Syndrome pipeline therapies in various stages of development include Soticlestat, Larcaserin,STK-001, and others.
Download sample report @ https://www.delveinsight.com/report-store/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dravet Syndrome Overview
Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Dravet Syndrome Foundation, states that DS is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures.
Dravet Syndrome Pipeline Analysis: Drug Profile
Lorcaserin: Eisai
Lorcaserin, a serotonin 2C receptor agonist, is being developed by Eisai. Lorcaserin works by selectively activating serotonin 2C receptors in the brain, through the activation GABAergic inhibitory interneuron, expected to suppress seizure of Dravet syndrome by increasing synaptic suppression from GABAergic. Although approval for the obesity indication has been voluntarily withdrawn, due to the request from Dravet syndrome patient groups, the extended access program has been continued in the United States, and the Phase III study is underway for this indication. The US FDA granted ODD for the treatment of Dravet Syndrome. Currently, the drug is in Phase III trials.
Discover more about the emerging Dravet Syndrome drugs @ https://www.delveinsight.com/report-store/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dravet Syndrome Key Companies
Takeda
Eisai
Stoke Therapeutics
And others
Dravet Syndrome Pipeline Therapies
Soticlestat
Larcaseri
STK-001
And others
Dravet Syndrome Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Dravet Syndrome Pipeline Report
Coverage: Global
Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeutics, and others
Key Dravet Syndrome Pipeline Therapies: Soticlestat, Larcaserin, STK-001, and others
Find out more about the Dravet Syndrome treatment options in development @ https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Leading Reports by DelveInsight:
· Asthma Diagnostic Devices Market
· Chronic Obstructive Pulmonary Disease Treatment Devices Market
· Airway Management Devices Market
· Cough Assist Devices Market
· Pulse Oximeters Market
· Hemodialysis Catheter Devices Market
· Chronic Spontaneous Urticaria Market
· Gender Dysphoria Market
· Germany Healthcare Outlook
· Biopsy Devices Pipeline Insight
· Bacterial Conjunctivitis Market
· Infliximab Biosimilar Insight
· Eosinophilic Asthma Market
· Cushing Syndrome Market
· Functional Dyspepsia Market
· Peripherally Inserted Central Catheters (PICC) Devices Market
Get detailed sample report by visiting here: https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.